Please check your internet connection and try again.
### Bricaciamab
#### Overview
Bricaciamab is a novel monoclonal antibody targeting a specific antigen on malignant B-cells. Its mechanism of action involves antibody-dependent cellular cytotoxicity (ADCC) and direct tumor cell apoptosis.
#### Primary Indications
* Relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
#### Adult Dosing
* **Standard Dose:** 1.5 mg/kg administered intravenously every 3 weeks for up to 8 cycles.
* **Maximum Dose:** Not explicitly defined beyond per-cycle calculation.
#### Pediatric Dosing
* Information on pediatric dosing is not established.
#### Dose Adjustments
* **Infusion Reactions:** Dose interruption, reduction, or permanent discontinuation may be necessary based on severity.
* **Febrile Neutropenia:** May require dose interruption or reduction.
#### Contraindications
* Known hypersensitivity to bricaciamab or its excipients.
#### Adverse Effects
* **Common:** Infusion-related reactions (fever, chills, rash, dyspnea), myelosuppression (neutropenia, thrombocytopenia, anemia), fatigue, nausea, diarrhea.
* **Serious:** Severe infusion reactions, tumor lysis syndrome, progressive multifocal leukoencephalopathy (PML) in rare cases.
#### Key Drug Interactions
* **Immunosuppressants:** Concomitant use should be approached with caution, as it may increase the risk of opportunistic infections or diminished response.
* **Live Vaccines:** Avoid administration during and for a period after treatment due to potential impaired immune response.
#### Monitoring
* **Hematologic Parameters:** Complete blood counts (CBC) with differential prior to each cycle and as clinically indicated.
* **Infusion Reactions:** Close monitoring during and after infusion.
* **Signs of Infection:** Monitor for fever and other signs of infection.
* **Renal and Hepatic Function:** Baseline and periodically as clinically indicated.
#### Clinical Pearls
* Infusion reactions are common and typically managed by slowing the infusion rate or administering pre-medications (e.g., acetaminophen, antihistamines, corticosteroids).
* Consider prophylactic agents for neutropenia based on individual risk assessment.
* Educate patients on signs and symptoms of infection and to report them promptly.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance.*
